<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jsms</journal-id><journal-title-group><journal-title xml:lang="ru">Journal of Siberian Medical Sciences</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of Siberian Medical Sciences</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2542-1174</issn><publisher><publisher-name>Federal state budgetary educational institution of higher education "Novosibirsk state medical university" of  Ministry of Health of the Russian Federation (FSBEI HE NSMU MOH Russia)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31549/2542-1174-2025-9-3-80-95</article-id><article-id custom-type="elpub" pub-id-type="custom">jsms-1230</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>Скрининг, стадирование и стратегии сохранения функции бета-клеток у пациентов с сахарным диабетом 1 типа</article-title><trans-title-group xml:lang="en"><trans-title>Screening, staging, and beta cell function preservation strategies in patients with type 1 DM</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6762-5238</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Руяткина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ruyatkina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Руяткина Людмила Александровна – д-р мед. наук, профессор кафедры неотложной терапии с эндокринологией и профпатологией</p><p>630091, г. Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Lyudmila A. Ruyatkina – Dr. Sci. (Med.), Professor, Department of Emergency Therapy with Endocrinology and Occupational Pathology</p><p>52, Krasny prosp., Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-1179-2002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Анмут</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Anmut</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Анмут Виктория Михайловна – клинический ординатор кафедры неотложной терапии с эндокринологией и профпатологией</p><p>630091, г. Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Victoria M. Anmut – Clinical Resident, Department of Emergency Therapy with Endocrinology and Occupational Pathology</p><p>52, Krasny prosp., Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5012-0364</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коваренко</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kovarenko</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Коваренко Маргарита Анатольевна – канд. мед. наук, доцент кафедры педиатрии (факультет повышения квалификации и профессиональной подготовки врачей)</p><p>630091, г. Новосибирск, Красный просп., 52</p></bio><bio xml:lang="en"><p>Margarita A. Kovarenko – Cand. Sci. (Med.), Associate Professor, Department of Pediatrics (Faculty of Advanced Training and Professional Training of Physicians)</p><p>52, Krasny prosp., Novosibirsk, 630091</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Novosibirsk State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>02</day><month>10</month><year>2025</year></pub-date><volume>0</volume><issue>3</issue><fpage>80</fpage><lpage>95</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Руяткина Л.А., Анмут В.М., Коваренко М.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Руяткина Л.А., Анмут В.М., Коваренко М.А.</copyright-holder><copyright-holder xml:lang="en">Ruyatkina L.A., Anmut V.M., Kovarenko M.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://jsms.elpub.ru/jour/article/view/1230">https://jsms.elpub.ru/jour/article/view/1230</self-uri><abstract><p>Настоящий обзор литературы включает анализ данных эпидемиологических исследований, метаанализов и научных публикаций, посвященных сахарному диабету 1 типа (СД1). Рассмотрены результаты исследований, оценивающих распространенность и заболеваемость СД1 в различных регионах мира, включая Россию. Выявлен повсеместный рост этих показателей во всех возрастных группах за последние 10 лет. Представлен анализ данных о генетических и средовых факторах риска развития СД1, включая возраст матери, ожирение, инфекции, дефицит витамина D. Рассмотрена классификация стадий СД1, отражающая континуум развития заболевания от появления аутоантител до клинических симптомов. Акцент сделан на доклинических стадиях СД1 и важности их ранней диагностики для потенциальной профилактики и замедления прогрессирования заболевания. Подчеркивается необходимость комплексного подхода к изучению СД1, учитывающего генетические, средовые и иммунологические аспекты заболевания. Знание факторов риска и стадийности развития СД1 позволяет разработать стратегии ранней диагностики и профилактики, направленные на замедление прогрессирования аутоиммунного процесса и предотвращенияе развития клинических проявлений диабета.</p></abstract><trans-abstract xml:lang="en"><p>This literature review includes an analysis of data from epidemiological studies, meta-analyses, and scientifi c publications on type 1 DM (T1DM). The results of studies assessing the prevalence and incidence of T1DM in various regions of the world, including Russia, are considered. A widespread increase in these indicators in all age groups over the past 10 years was found. An analysis of data on genetic and environmental risk factors for the development of T1DM, including maternal age, obesity, infections, and vitamin D defi ciency is presented. A classifi cation of T1DM stages is considered, refl ecting the continuum of disease development from the appearance of autoantibodies to clinical symptoms. The emphasis is on the preclinical stages of T1DM and the importance of their early diagnosis for potential prevention and delay of disease progression. The need for an integrated approach to the study of T1DM, taking into account the genetic, environmental, and immunological aspects of the disease, is emphasized. Knowledge of risk factors and stages of development of T1DM allows us to develop strategies for early diagnosis and prevention aimed at delay in the progression of the autoimmune process and development of clinical manifestations of T1DM.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 1 типа</kwd><kwd>доклинические стадии</kwd><kwd>аутоантитела</kwd><kwd>скрининг</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 1 DM</kwd><kwd>preclinical stages</kwd><kwd>autoantibodies</kwd><kwd>screening</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Akil A.A., Yassin E., Al-Maraghi A. et al. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era // J. Transl. Med. 2021;19(1):137. DOI: 10.1186/s12967-021-02778-6.</mixed-citation><mixed-citation xml:lang="en">Akil A.A., Yassin E., Al-Maraghi A. et al. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era. J. Transl. Med. 2021;19(1):137. DOI: 10.1186/s12967-021-02778-6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fanaropoulou N.M., Tsatsani G.C., Koufakis T., Kotsa K. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function // Expert Rev. Clin. Immunol. 2024;20(2):185- 196. DOI: 10.1080/1744666X.2023.2281990.</mixed-citation><mixed-citation xml:lang="en">Fanaropoulou N.M., Tsatsani G.C., Koufakis T., Kotsa K. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function. Expert Rev. Clin. Immunol. 2024;20(2):185- 196. DOI: 10.1080/1744666X.2023.2281990.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">So M., Speake C., Steck A.K. et al. Advances in type 1 diabetes prediction using islet autoantibodies: beyond a simple count // Endocr. Rev. 2021;42(5):584-604. DOI: 10.1210/endrev/bnab013.</mixed-citation><mixed-citation xml:lang="en">So M., Speake C., Steck A.K. et al. Advances in type 1 diabetes prediction using islet autoantibodies: beyond a simple count. Endocr. Rev. 2021;42(5):584-604. DOI: 10.1210/endrev/bnab013.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classifi cation of Diabetes: Standards of Care in Diabetes–2024 // Diabetes Care. 2024;47(Suppl 1):S20-S42. DOI: 10.2337/dc24-S002.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classifi cation of Diabetes: Standards of Care in Diabetes–2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. DOI: 10.2337/dc24-S002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Haller M.J., Bell K.J., Besser R.E.J. et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes // Horm. Res. Paediatr. 2024;97(6):529-545. DOI: 10.1159/000543035.</mixed-citation><mixed-citation xml:lang="en">Haller M.J., Bell K.J., Besser R.E.J. et al. ISPAD Clinical Practice Consensus Guidelines 2024: Screening, staging, and strategies to preserve beta-cell function in children and adolescents with type 1 diabetes. Horm. Res. Paediatr. 2024;97(6):529-545. DOI: 10.1159/000543035.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schatz D.A., Bingley P.J. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT) // J. Pediatr. Endocrinol. Metab. 2001;14(Suppl 1):619- 622. DOI: 10.1515/jpem.2001.14.s1.619.</mixed-citation><mixed-citation xml:lang="en">Schatz D.A., Bingley P.J. Update on major trials for the prevention of type 1 DM: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J. Pediatr. Endocrinol. Metab. 2001;14(Suppl 1):619-622. DOI: 10.1515/jpem.2001.14.s1.619.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Безлепкина О.В., Шешко Е.Л. и др. Основные эпидемиологические показатели сахарного диабета 1 типа у детей в Российской Федерации за 2014–2023 годы // Проблемы эндокринологии. 2024;70(5):76-83. DOI: 10.14341/probl13515.</mixed-citation><mixed-citation xml:lang="en">Laptev D.N., Bezlepkina O.V., Sheshko E.L. et al. Main epidemiological indicators of type 1 diabetus mellitus in children in the Russian Federation for 2014–2023. Problems of Endocrinology. 2024;70(5):76-83. DOI: 10.14341/probl13515. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Patterson C.C., Harjutsalo V., Rosenbauer J. et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study // Diabetologia. 2019;62(3):408- 417. DOI: 10.1007/s00125-018-4763-3.</mixed-citation><mixed-citation xml:lang="en">Patterson C.C., Harjutsalo V., Rosenbauer J. et al. Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989–2013: a multicentre prospective registration study. Diabetologia. 2019;62(3):408-417. DOI: 10.1007/s00125-018-4763-3.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Insel R.A., Dunne J.L., Atkinson M.A. et al. Staging presymptomatic type 1 diabetes: a scientifi c statement of JDRF, the Endocrine Society, and the American Diabetes Association // Diabetes Care. 2015;38(10):1964-1974. DOI: 10.2337/dc15-1419.</mixed-citation><mixed-citation xml:lang="en">Insel R.A., Dunne J.L., Atkinson M.A. et al. Staging presymptomatic type 1 diabetes: a scientifi c statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964- 1974. DOI: 10.2337/dc15-1419.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y., Qian K., Wu D. et al. Incidence of childhood type 1 diabetes in Beijing during 2011–2020 and predicted incidence for 2025–2035: a multicenter, hospitalization-based study // Diabetes Ther. 2023;14(3):519- 529. DOI: 10.1007/s13300-023-01367-8</mixed-citation><mixed-citation xml:lang="en">Li Y., Qian K., Wu D. et al. Incidence of childhood type 1 diabetes in Beijing during 2011–2020 and predicted incidence for 2025–2035: a multicenter, hospitalization-based study. Diabetes Ther. 2023;14(3):519- 529. DOI: 10.1007/s13300-023-01367-8</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Knip M. Type 1 diabetes in Finland: past, present, and future // Lancet Diabetes Endocrinol. 2021;9(5):259- 260. DOI: 10.1016/S2213-8587(21)00074-7.</mixed-citation><mixed-citation xml:lang="en">Knip M. Type 1 diabetes in Finland: past, present, and future. Lancet Diabetes Endocrinol. 2021;9(5):259- 260. DOI: 10.1016/S2213-8587(21)00074-7.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Hussein S., Bandarian F., Salehi N. et al. The eff ect of vitamin D defi ciency on immune-related hub genes: a network analysis associated with type 1 diabetes // Cureus. 2024;16(9):e68611. DOI: 10.7759/ cureus.68611.</mixed-citation><mixed-citation xml:lang="en">Hussein S., Bandarian F., Salehi N. et al. The eff ect of vitamin D defi ciency on immune-related hub genes: a network analysis associated with type 1 diabetes. Cureus. 2024;16(9):e68611. DOI: 10.7759/cureus.68611.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hippich M., Beyerlein A., Hagopian W.A. et al.; TEDDY Study Group; Teddy Study Group. Genetic contribution to the divergence in type 1 diabetes risk between children from the general population and children from aff ected families // Diabetes. 2019;68(4):847- 857. DOI: 10.2337/db18-0882.</mixed-citation><mixed-citation xml:lang="en">Hippich M., Beyerlein A., Hagopian W.A. et al.; TEDDY Study Group; Teddy Study Group. Genetic contribution to the divergence in type 1 diabetes risk between children from the general population and children from aff ected families. Diabetes. 2019;68(4):847-857. DOI: 10.2337/db18-0882.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Redondo M.J., Gignoux C.R., Dabelea D. et al. Type 1 diabetes in diverse ancestries and the use of genetic risk scores // Lancet Diabetes Endocrinol. 2022;10(8):597- 608. DOI: 10.1016/S2213-8587(22)00159-0.</mixed-citation><mixed-citation xml:lang="en">Redondo M.J., Gignoux C.R., Dabelea D. et al. Type 1 diabetes in diverse ancestries and the use of genetic risk scores. Lancet Diabetes Endocrinol. 2022;10(8):597- 608. DOI: 10.1016/S2213-8587(22)00159-0.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Norris J.M., Johnson R.K., Stene L.C. Type 1 diabetesearly life origins and changing epidemiology // Lancet Diabetes Endocrinol. 2020;8(3):226-238. DOI: 10.1016/S2213-8587(19)30412-7.</mixed-citation><mixed-citation xml:lang="en">Norris J.M., Johnson R.K., Stene L.C. Type 1 diabetesearly life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020;8(3):226-238. DOI: 10.1016/S2213-8587(19)30412-7.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cardwell C.R., Stene L.C., Joner G. et al. Maternal age at birth and childhood type 1 diabetes: a pooled analysis of 30 observational studies // Diabetes. 2010;59(2):486-494. DOI: 10.2337/db09-1166.</mixed-citation><mixed-citation xml:lang="en">Cardwell C.R., Stene L.C., Joner G. et al. Maternal age at birth and childhood type 1 diabetes: a pooled analysis of 30 observational studies. Diabetes. 2010;59(2):486- 494. DOI: 10.2337/db09-1166.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Censin J.C., Nowak C., Cooper N. et al. Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study // PLoS Med. 2017;14(8):e1002362. DOI: 10.1371/journal.pmed.1002362.</mixed-citation><mixed-citation xml:lang="en">Censin J.C., Nowak C., Cooper N. et al. Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study. PLoS Med. 2017;14(8):e1002362. DOI: 10.1371/journal.pmed.1002362.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Calvo T. Enteroviral infections as a trigger for type 1 diabetes // Curr. Diab. Rep. 2018;18(11):106. DOI: 10.1007/s11892-018-1077-2.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Calvo T. Enteroviral infections as a trigger for type 1 diabetes. Curr. Diab. Rep. 2018;18(11):106. DOI: 10.1007/s11892-018-1077-2.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Karavanaki K., Rodolaki K., Soldatou A. et al. Covid-19 infection in children and adolescents and its association with type 1 diabetes mellitus (T1d) presentation and management// Endocrine. 2023;80(2):237-252. DOI: 10.1007/s12020-022-03266-7.</mixed-citation><mixed-citation xml:lang="en">Karavanaki K., Rodolaki K., Soldatou A. et al. Covid-19 infection in children and adolescents and its association with type 1 DM (T1d) presentation and management. Endocrine. 2023;80(2):237-252. DOI: 10.1007/s12020-022-03266-7.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Li C., Fu J., Ye Y. et al. The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults // Front. Endocrinol. (Lausanne). 2024;15:1360525. DOI: 10.3389/fendo.2024.1360525.</mixed-citation><mixed-citation xml:lang="en">Li C., Fu J., Ye Y. et al. The impact of vitamin D on the etiopathogenesis and the progression of type 1 and type 2 diabetes in children and adults. Front. Endocrinol. (Lausanne). 2024;15:1360525. DOI: 10.3389/fendo.2024.1360525.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Klenczar-Kciuk K.M., Seget S., Adamczyk P., JaroszChobot P. Vitamin D defi ciency is common among Polish children with newly diagnosed type 1 diabetes mellitus // Endokrynol. Pol. 2025;76(1):59-65. DOI: 10.5603/ep.100801.</mixed-citation><mixed-citation xml:lang="en">Klenczar-Kciuk K.M., Seget S., Adamczyk P., JaroszChobot P. Vitamin D defi ciency is common among Polish children with newly diagnosed type 1 DM. Endokrynol. Pol. 2025;76(1):59-65. DOI: 10.5603/ ep.100801.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Joshi K., Harris M., Cotterill A. et al. Continuous glucose monitoring has an increasing role in presymptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing // Clin. Chem. Lab. Med. 2023;62(1):41-49. DOI: 10.1515/cclm-2023-0234.</mixed-citation><mixed-citation xml:lang="en">Joshi K., Harris M., Cotterill A. et al. Continuous glucose monitoring has an increasing role in presymptomatic type 1 diabetes: advantages, limitations, and comparisons with laboratory-based testing. Clin. Chem. Lab. Med. 2023;62(1):41-49. DOI: 10.1515/cclm-2023-0234.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sims E.K., Besser R.E.J., Dayan C. et al.; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for type 1 diabetes in the general population: A status report and perspective // Diabetes. 2022;71(4):610-623. DOI: 10.2337/dbi20-0054.</mixed-citation><mixed-citation xml:lang="en">Sims E.K., Besser R.E.J., Dayan C. et al.; NIDDK Type 1 Diabetes TrialNet Study Group. Screening for type 1 diabetes in the general population: A status report and perspective. Diabetes. 2022;71(4):610-623. DOI: 10.2337/dbi20-0054.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Besser R.E.J., Ng S.M., Gregory J.W. et al. General population screening for childhood type 1 diabetes: is it time for a UK strategy? // Arch. Dis. Child. 2022;107(9):790-795. DOI: 10.1136/archdischild-2021-321864.</mixed-citation><mixed-citation xml:lang="en">Besser R.E.J., Ng S.M., Gregory J.W. et al. General population screening for childhood type 1 diabetes: is it time for a UK strategy? Arch. Dis. Child. 2022;107(9):790- 795. DOI: 10.1136/archdischild-2021-321864.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Sherwani S.I., Khan H.A., Ekhzaimy A. et al. Signifi cance of HbA1c test in diagnosis and prognosis of diabetic patients // Biomark. Insights. 2016;11:95- 104. DOI: 10.4137/BMI.S38440.</mixed-citation><mixed-citation xml:lang="en">Sherwani S.I., Khan H.A., Ekhzaimy A. et al. Signifi cance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark. Insights. 2016;11:95-104. DOI: 10.4137/BMI.S38440.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Bonifacio E., Weiß A., Winkler C. et al.; TEDDY Study Group. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood // Diabetes Care. 2021;44(10):2260-2268. DOI: 10.2337/dc20-2122.</mixed-citation><mixed-citation xml:lang="en">Bonifacio E., Weiß A., Winkler C. et al.; TEDDY Study Group. An age-related exponential decline in the risk of multiple islet autoantibody seroconversion during childhood. Diabetes Care. 2021;44(10):2260-2268. DOI: 10.2337/dc20-2122.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ghalwash M., Dunne J.L., Lundgren M. et al.; Type 1 Diabetes Intelligence Study Group. Two-age isletautoantibody screening for childhood type 1 diabetes: a prospective cohort study // Lancet Diabetes Endocrinol. 2022;10(8):589-596. DOI: 10.1016/S2213-8587(22)00141-3.</mixed-citation><mixed-citation xml:lang="en">Ghalwash M., Dunne J.L., Lundgren M. et al.; Type 1 Diabetes Intelligence Study Group. Two-age isletautoantibody screening for childhood type 1 diabetes: a prospective cohort study. Lancet Diabetes Endocrinol. 2022;10(8):589-596. DOI: 10.1016/S2213-8587(22)00141-3.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ghalwash M., Anand V., Lou O. et al.; Type 1 Diabetes Intelligence Study Group. Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study // Lancet Child Adolesc. Health. 2023;7(4):261-268. DOI: 10.1016/S2352-4642(22)00350-9.</mixed-citation><mixed-citation xml:lang="en">Ghalwash M., Anand V., Lou O. et al.; Type 1 Diabetes Intelligence Study Group. Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. Lancet Child Adolesc. Health. 2023;7(4):261-268. DOI: 10.1016/S2352-4642(22)00350-9.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Vehik K., Bonifacio E., Lernmark Å. et al.; TEDDY Study Group. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY Study // Diabetes Care. 2020;43(9):2066- 2073. DOI: 10.2337/dc19-2547.</mixed-citation><mixed-citation xml:lang="en">Vehik K., Bonifacio E., Lernmark Å. et al.; TEDDY Study Group. Hierarchical order of distinct autoantibody spreading and progression to type 1 diabetes in the TEDDY Study. Diabetes Care. 2020;43(9):2066- 2073. DOI: 10.2337/dc19-2547.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Frohnert B.I., Ghalwash M., Li Y. et al.; T1DI Study Group. Refining the definition of stage 1 type 1 diabetes: an ontology-driven analysis of the heterogeneity of multiple islet autoimmunity // Diabetes Care. 2023;46(10):1753-1761. DOI: 10.2337/dc22-1960.</mixed-citation><mixed-citation xml:lang="en">Frohnert B.I., Ghalwash M., Li Y. et al.; T1DI Study Group. Refining the definition of stage 1 type 1 diabetes: an ontology-driven analysis of the heterogeneity of multiple islet autoimmunity. Diabetes Care. 2023;46(10):1753-1761. DOI: 10.2337/dc22-1960.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Phillip M., Achenbach P., Addala A. et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes // Diabetes Care. 2024;47(8):1276-1298. DOI: 10.2337/dci24-0042.</mixed-citation><mixed-citation xml:lang="en">Phillip M., Achenbach P., Addala A. et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024;47(8):1276-1298. DOI: 10.2337/dci24-0042.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Thakkar S., Chopra A., Nagendra L. et al. Teplizumab in type 1 diabetes mellitus: an updated review // touchREV Endocrinol. 2023;19(2):22-30. DOI: 10.17925/ EE.2023.19.2.7.</mixed-citation><mixed-citation xml:lang="en">Thakkar S., Chopra A., Nagendra L. et al. Teplizumab in type 1 DM: an updated review. touchREV Endocrinol. 2023;19(2):22-30. DOI: 10.17925/EE.2023.19.2.7.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Лаптев Д.Н., Дедов И.И. На пути к профилактике сахарного диабета 1 типа: зарегистрирован первый в истории препарат, замедляющий развитие аутоиммунного процесса // Сахарный диабет. 2022;25(6):576-579. DOI: 10.14341/DM12988.</mixed-citation><mixed-citation xml:lang="en">Laptev D.N., Dedov I.I. Towards prevention of type 1 diabetes: FDA approved fi rst drug with potential to delay clinical stage of disease. Diabetus Mellitus. 2022;25(6):576-579. DOI: 10.14341/DM12988. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Keam S.J. Teplizumab: fi rst approval // Drugs. 2023;83(5):439-445. DOI: 10.1007/s40265-023-01847-y.</mixed-citation><mixed-citation xml:lang="en">Keam S.J. Teplizumab: fi rst approval. Drugs. 2023;83(5):439-445. DOI: 10.1007/s40265-023- 01847-y.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos E.L., Dayan C.M., Chatenoud L. et al.; PROTECT Study Investigators. Teplizumab and β-cell function in newly diagnosed type 1 diabetes // N. Engl. J. Med. 2023;389(23):2151-2161. DOI: 10.1056/NEJMoa2308743.</mixed-citation><mixed-citation xml:lang="en">Ramos E.L., Dayan C.M., Chatenoud L. et al.; PROTECT Study Investigators. Teplizumab and β-cell function in newly diagnosed type 1 diabetes. N. Engl. J. Med. 2023;389(23):2151-2161. DOI: 10.1056/NEJMoa2308743.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Herold K.C., Gitelman S.E., Gottlieb P.A. et al. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function // Diabetes Care. 2023;46(10):1848-1856. DOI: 10.2337/dc23-0675.</mixed-citation><mixed-citation xml:lang="en">Herold K.C., Gitelman S.E., Gottlieb P.A. et al. Teplizumab: a disease-modifying therapy for type 1 diabetes that preserves β-cell function. Diabetes Care. 2023;46(10):1848-1856. DOI: 10.2337/dc23-0675.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Sims E.K., Bundy B.N., Stier K. et al.; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals // Sci. Transl. Med. 2021;13(583):eabc8980. DOI: 10.1126/scitranslmed.abc8980.</mixed-citation><mixed-citation xml:lang="en">Sims E.K., Bundy B.N., Stier K. et al.; Type 1 Diabetes TrialNet Study Group. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci. Transl. Med. 2021;13(583):eabc8980. DOI: 10.1126/scitranslmed.abc8980.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
